BiotechTV - News Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist
8 snips
Feb 11, 2026 Rand Sutherland, CEO of Upstream Bio and developer of verekitug, a TSLP receptor antagonist for respiratory and type 2 inflammatory disease. He walks through top-line severe asthma data across multiple doses. He explains the striking high-dose Q12-week results, dosing-frequency advantages versus monthly competitors, and plans for phase 3, regulators, and additional CRS and COPD programs.
AI Snips
Chapters
Transcript
Episode notes
Team Credit For The Data
- Rand credits the full Upstream team for the work and results rather than taking personal credit.
- He emphasizes pride in being part of the team behind the data.
Strong Efficacy With Quarterly Dosing
- Varecitug (TSLP receptor antibody) delivered a 56% reduction in annualized severe asthma exacerbations at 100 mg every 12 weeks versus placebo.
- It also produced significant FEV1 and exhaled nitric oxide improvements, showing broad pharmacologic effect at four-times-per-year dosing.
Mixed Results For Twice-Yearly Regimens
- Twice-yearly (Q24w) 400 mg dosing also significantly reduced exacerbations and improved lung function and airway inflammation.
- The 100 mg Q24w arm was intentionally sub-therapeutic and showed weaker secondary endpoint effects.